Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of cancer treatment, leading to bleeding and dose reductions.
• Currently, no widely approved therapies exist for managing CIT.
• CIT can negatively impact treatment intensity and patient prognosis.

Purpose of the Study:

• To evaluate the efficacy and safety of romiplostim in treating persistent CIT in patients undergoing oxaliplatin-based chemotherapy.
• To determine if romiplostim can prevent chemotherapy dose modifications due to low platelet counts.

Main Methods:

• A phase 3, international, double-blind, randomized, placebo-controlled trial was conducted.
• 165 patients with persistent CIT receiving oxaliplatin-based chemotherapy were randomized (2:1) to romiplostim or placebo for three cycles.
• The primary endpoint was the absence of CIT-induced chemotherapy dose modifications in cycles 2 and 3.

Main Results:

• 84% of patients receiving romiplostim experienced no chemotherapy dose modifications compared to 36% in the placebo group (OR 10.16, P<0.001).
• Adverse events of grade 3 or higher were more frequent in the romiplostim group (37%) versus placebo (22%), primarily reflecting chemotherapy effects.
• Investigator-reported romiplostim-related adverse events were infrequent (12%) and not serious; thromboembolic events occurred in 2% of the romiplostim group.

Conclusions:

• Romiplostim demonstrated significant efficacy in treating chemotherapy-induced thrombocytopenia.
• The drug helped maintain chemotherapy dose intensity, suggesting a potential benefit for patients with gastrointestinal cancers.
• Romiplostim was generally well-tolerated, with manageable adverse events.